ImmunityBio, Inc. 8-K

What Happened
ImmunityBio, Inc. issued a press release on April 9, 2026 (filed as an 8-K, Item 2.02) announcing preliminary, unaudited financial results for the fiscal quarter ended March 31, 2026. The company said these amounts are preliminary estimates based on information available as of the press release date and are not a comprehensive statement of operating results or financial position. Final results will be subject to the company’s financial closing procedures and may differ materially from these preliminary estimates when reported in the Quarterly Report on Form 10‑Q.

Key Details

• Press release dated April 9, 2026; 8-K furnished under Item 2.02.
• Results cover the fiscal quarter ended March 31, 2026 and are described as preliminary and unaudited.
• The company warned amounts are subject to final closing procedures and adjustments and may materially differ from the figures in the forthcoming Form 10‑Q.
• The press release was furnished as Exhibit 99.1 to the 8‑K.

Why It Matters
Retail investors should treat the announced figures as preliminary estimates, not final earnings or revenue results. Because the numbers are unaudited and may change with the company’s closing procedures, the definitive financial picture will come when ImmunityBio files its Form 10‑Q. Investors who base decisions on quarterly results should wait for the finalized 10‑Q disclosure for confirmed revenue, earnings and balance sheet figures.